Truveta Tru enables researchers to accelerate their medical research
Truveta Studio now includes Truveta Tru, a research assistant powered by generative AI
October 29, 2024 09:18 ET | Truveta
BELLEVUE, Wash., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Today, Truveta announced its latest AI innovation – Truveta Tru, Truveta Studio’s research assistant powered by generative AI. Trained on the...
The University of Washington's CHOICE Institute partners with Truveta to advance health economics and outcomes research
The CHOICE Institute partners with Truveta to advance health economics and outcomes research
September 04, 2024 09:00 ET | Truveta
BELLEVUE and SEATTLE, Wash., Sept. 04, 2024 (GLOBE NEWSWIRE) -- The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute at the University of Washington’s School of Pharmacy has...
Truveta Research study published in JAMA Internal Medicine compares tirzepatide (Mounjaro) and semaglutide (Ozempic) for weight loss
Truveta’s real-world data study comparing tirzepatide (Mounjaro) and semaglutide (Ozempic) for weight loss published in JAMA Internal Medicine
July 08, 2024 11:16 ET | Truveta
BELLEVUE, Wash., July 08, 2024 (GLOBE NEWSWIRE) -- Today Truveta announced that its comparative effectiveness study exploring weight loss among patients taking semaglutide (Ozempic) and tirzepatide...
Truveta is a growing collective of health systems in the US with a mission of Saving Lives with Data.
Truveta announces support for regulatory submissions to the FDA and global regulatory authorities
June 18, 2024 11:13 ET | Truveta
BELLEVUE, Wash., June 18, 2024 (GLOBE NEWSWIRE) -- Today, Truveta announced regulatory and audit capabilities to support its customers for real-world evidence (RWE) submissions to the Food and Drug...
Truveta now empowers researchers to learn from millions of de-identified medical images – across all modalities, including MRI, CT, X-ray, ultrasound, mammogram, and nuclear medicine – integrated with the patient’s EHR data.
Using clinical-led AI, Truveta expands clinical notes and medical images available to advance research
May 02, 2024 09:00 ET | Truveta
BELLEVUE, Wash., May 02, 2024 (GLOBE NEWSWIRE) -- Today Truveta announced the availability of expanded concepts from clinical notes -- including family history, medication details reported to...
Exploring a mother-child patient population for which mothers received a flu vaccine during pregnancy to understand virus protection for the child after birth using Truveta Studio
Truveta delivers largest and most complete mother and child EHR dataset to advance healthcare
April 25, 2024 09:00 ET | Truveta
BELLEVUE, Wash., April 25, 2024 (GLOBE NEWSWIRE) -- Truveta, the company with a mission of Saving Lives with Data, announced today the largest and most complete mother-child electronic health record...
Truveta is a growing collective of health systems that provide more than 18% of all daily clinical care in the US.
More than 50 organizations choose Truveta for the most complete, timely, and clean EHR data to study safety and effectiveness, improve patient care, and train medical AI
October 23, 2023 09:00 ET | Truveta
Bellevue, WASH., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Truveta announced today that it is partnering with more than 50 organizations in life sciences, healthcare, government, academic medical centers,...
Meet Axtria at ISPORT 2023
Gold Sponsor, Axtria Presents a Thought-Provoking Workshop on “Does Geography Affect Your Health?” and Six Additional HEOR/RWE Studies at ISPOR 2023
April 27, 2023 09:30 ET | Axtria Inc.
Boston, Massachusetts, April 27, 2023 (GLOBE NEWSWIRE) -- Axtria Inc., a global leader of award-winning cloud software and an integrated RWE/HEOR analytics solution provider, will present research...
Xtalks Webinar - Verana Health & Axtria
Axtria® To Talk About How Electronic Health Record Real-world Data Can Augment Clinical Insights on Xtalks Webinar
June 20, 2022 08:00 ET | Axtria Inc.
Berkeley Heights, NJ, June 20, 2022 (GLOBE NEWSWIRE) -- With real-world evidence (RWE) increasingly being discussed as an important indicator for determining the value of new patient therapies and...